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Some murine retroviruses exhibit altered release of virus when cells are treated with alpha interferon
(IFN-oa), resulting in the accumulation of intraceUlular virions in cytoplasmic vacuoles. In studies of the
inhibitory effect of IFN-ac (Welferon) on acute human immunodeficiency virus type 1 infection of human T-cell
lines, we found that in C3 cells, the 50% effective concentration was 9 U/ml and the 90% effective concentration
was 310 U/ml. There was no apparent accumulation of intracelular particles detected by p24 antigen levels or
by processing the cells for electron microscopy. ExtraceUlular reverse transcriptase activity and p24 levels
decreased in parallel with increasing IFN, whereas the intracellular viral proteins decreased only slightly. By
electron microscopy, cells treated with higher concentrations of IFN (512 U/mi) disclosed very few particles
budding into extracellular spaces; no intracellular particles could be seen, despite nearly normal levels of
intracellular viral protein detected by the p24 antigen assay and correct processing detected by Western blot
(immunoblot) analysis. Thus in human immunodeficiency virus-infected cells, the major block produced by
IFN-a appeared to be late in the viral cycle at the morphogenesis stage of virion production. Chronically
infected Jurkat cells treated with IFN appeared to be inhibited in growth rate, as virus production decreased
proportionally with cell number.
In addition to their effects upon cells, interferons (IFNs)
have various antiviral effects (for a review, see reference 17),
including the inhibition of assembly, maturation, and release
in murine leukemia virus systems. In chronically infected
cells, depending on the virus and cell system used, IFN
appears to inhibit at a late stage of morphogenesis, either
drastically inhibiting virus production, with an accumulation
of virus particles on the cell surface, or causing release of
fewer, noninfectious particles (1, 3, 14, 17). In addition,
infection and transformation of cells with murine sarcoma]
leukemia viruses is blocked by IFN probably at the level of
synthesis and integration of proviral DNA (2, 11). In the
avian retrovirus system, both early effects at or before
proviral DNA synthesis and late effects on virus maturation
have been noted (20, 29). Zens et al. (28) have recently
shown that uncoating and reverse transcription are inhibited
in de novo infection of chicken embryo fibroblasts by Rous
sarcoma virus.
Ho et al. (9) have reported a dose-related antiviral effect of
alpha interferon (IFN-a) against human immunodeficiency
virus (HIV) replication in peripheral blood mononuclear
cells. Inhibition of acute HIV infection has been reported in
the same cells, as have inhibition of chronically infected H9
cells (7) and synergy of 3'-azido-2',3'-dideoxythymidine
(AZT) and IFN-a against HIV replication (8; our unpub-
lished results). Vogt et al. (24) have reported synergistic
inhibition of HIV by the combination of IFN-a and 2',-3'-
dideoxycytidine. Other synergistic combinations active
against HIV replication are AZT plus phosphonylmethoxy-
ethyladenine (PMEA; 18), AZT plus carbocyclic-2',3'-dide-
hydro-2',3'-dideoxyguanosine (carbovir; 19a), and AZT plus
2',3'-dideoxyinosine (la).
In view of the considerable interest in the clinical use of
IFN-a for HIV-infected persons, we investigated the effect
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of IFN-a (Wellferon) on acute and chronic human immuno-
deficiency virus type 1 (HIV-1) infection of three human
T-lymphocyte cell lines in culture. In acute infections, we
found a slight decrease in viral RNA synthesis and viral
protein synthesis at the highest level of IFN used, whereas
the production of extracellular virus particles decreased
disproportionately as measured by reverse transcriptase
activity (RT) and p24 antigen in supernatant medium. This
decreased extracellular virus production was confirmed by
electron microscopy. No changes in the processing of pre-
cursor protein to the final products were seen.
MATERIALS AND METHODS
Cels, virus, and IFN. The lymphadenopathy virus type 1
strain (BRU) of HIV-1 was obtained from L. Montagnier,
and stocks were prepared in C3 or H9 cells. The human
T-cell, H9, CEM, C3, and Jurkat cell lines were grown in
RPMI 1640 medium with 8% fetal calf serum. Cells were
infected in the presence of 2 ,ug of DEAE-dextran per ml for
60 min at 37°C, washed twice in medium, and placed in
medium containing IFN. In some experiments, duplicate or
triplicate wells of each treatment were analyzed. IFN-a was
a gift from the Burroughs Wellcome Co., Research Triangle
Park, N.C. H9, CEM, C3, and Jurkat cells were the gifts of
R. Gallo, S. Carter, W. Mitchell, and the National Institute
of Allergy and Infectious Diseases AIDS Reference Reagent
Repository Program, respectively. Infectious titers of HIV
were determined by infection of 10i CEM cells in triplicate
with 1:5 dilutions of virus-containing medium. Positive wells
were determined by RT assay at day 6 postinfection (p.i.),
and titers were calculated by the method of Reed and
Muench (16). Three human T-cell lines were used in these
experiments to avoid overgeneralization which might result
from the use of a single cell line.
RT assay and p24 ELISA. Virus-associated RT was as-
sayed in duplicate 50-pil reaction mixtures containing 30 p,l of
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unconcentrated, clarified supernatant medium and 5 ,Ci of
[3H]TTP (specific activity, 60 to 80 Ci/mmol; Amersham
Corp.) with the addition of 10 mM Tris hydrochloride (pH
7.5), 8 mM MgCl2, 10 mM dithiothreitol, 0.5% Triton X-100,
50 ,ug of poly(A) per ml, and 10 ,ug of oligo(dT)12_18 (Phar-
macia, Inc.) per ml. After 45 min at 37°C, 40 pul of each
reaction mixture was spotted onto DE81 paper (Whatman,
Inc.), the paper was washed, and radioactivity was counted
as described previously (19). Standard deviations of the
means for RT assays were approximately 10%. p24 levels
were determined on two dilutions of supernatant medium or
cellular lysate, each in duplicate, by antigen capture en-
zyme-linked immunosorbent assay (ELISA) (Dupont), as
directed by the manufacturer. The sensitivity of this assay is
not affected by cellular protein. The standard deviations of
the means of p24 determinations averaged 15%.
Electron microscopy. Cell samples from each IFN concen-
tration tested were isolated by low-speed centrifugation to
be evaluated by electron microscopy (12). The cell pellets
were washed briefly with cold 2% cacodylate buffer contain-
ing 5% sucrose (pH 7.6) and fixed in 2% buffered glutaral-
dehyde. Following postfixation in 2% OS04, dehydration,
and embedding in an Epon-Araldite composite resin, thin
sections were cut from several levels within the core of the
pellet, stained sequentially with uranyl acetate and lead
citrate, and viewed in a Philips 400 TLG transmission
electron microscope. The cell pellets were not disturbed
throughout the embedding process.
Western blots (immunoblots). Cells were washed with
phosphate-buffered saline (PBS) and lysed in Tris-buffered
saline containing 0.5% Triton X-100, 0.5% sodium deoxy-
cholate, and 1 mM phenylmethylsulfonyl fluoride; sheared
by treatment in a Vortex mixer; held overnight at 4°C; and
clarified at 10,000 x g for 10 min. The protein concentration
in the supernatant fluid was determined by the Bio-Rad
protein assay, with bovine serum albumin as the protein
standard. Fifty micrograms of cellular protein per lane was
electrophoresed on 12% acrylamide gels and electroblotted
onto Immobilon filters (Millipore; 23). The filters were
reacted with normal or AIDS patient serum followed by
anti-human immunoglobulin-alkaline phosphatase and de-
veloped in 0.33 mg of Nitro Blue Tetrazolium per ml-0.165
mg of 5-bromo-4-chloro-3-indolyl phosphate per ml (10).
Determination of the EC50 and EC90. The values of the 50%
effective concentration (EC50) and EC90 for inhibition of
virus replication and the correlation coefficient (r) were
determined by using software developed by Chou and Chou
(4) based on the median-effect equations of Chou and Talalay
(5).
RESULTS
Inhibition of virus production by IFN. H9 cells were
infected with HIV, washed, and placed into medium con-
taining various concentrations of IFN. Virus production at
days 5 and 8 p.i. was determined by RT assays of the
supernatant medium. C3 cells were similarly infected and
sampled on days 4 and 8 p.i. With the use of the median-
effect equation of Chou and Talalay, the H9 EC50 (day 8) was
calculated to be 35 U/ml and the EC90 was calculated to be
400 U/ml (r = 0.997). From two C3 cell experiments, the
average EC50 and EC90 were calculated to be 9 and 310 U/ml
(r = 0.84 and 0.92), respectively.
H9 cells were infected as described above and placed into
various levels of IFN. At day 5 p.i., the cells were split 1:5
(also in IFN); on day 7 p.i., samples of supernatant medium
were collected for an RT assay and the cell pellets were
processed for electron microscopy. Control infected cells
(RT = 23,256 cpm; range, 20,085 to 26,432 cpm) commonly
showed virus budding from the plasma membrane and nu-
merous free virions in fields surrounding cells (Fig. 1A). In
contrast, the infected cells treated with 512 U of IFN (RT =
576 cpm; range, 559 to 593 cpm; average background, 181
cpm; 98.3% reduction after background) per ml showed very
few extracellular particles (Fig. 1B), and there was no
evidence of intracellular accumulation of cores. Budding
was rarely observed in the IFN-treated cells. Intermediate
levels of IFN treatment resulted in intermediate levels of
extracellular virus particles. In general, increasing concen-
trations of IFN resulted in decreasing numbers of virus-
producing cells in the numerous sections evaluated from
each sample. The ultrastructural appearance of the virions
assembled in the presence of IFN did not differ detectably
from those of the non-IFN-treated controls.
Toxicity of IFN for uninfected cells. In toxicity tests of the
IFN preparation on uninfected Jurkat and H9 cells, the
concentration of IFN required to decrease by 50% the total
cell number at day 4 in growth curves was greater than 128
U/ml. Jurkat cells set up at 9.7 x 104/ml were inhibited 31%
at 128 U/ml on day 4 (4.11 x 105/ml versus 5.99 x 105/ml).
H9 cells set up at 9.3 x 104/ml were 32% inhibited at 128
U/ml on day 4 (1.94 x 105/ml versus 2.87 x 105/ml). In Jurkat
cells, the viability after 4 days at 128 U/ml was 90%, whereas
the viability of the non-IFN-treated control was 95%.
Reduction of intracellular versus extracellular p24 levels.
C3 cells were infected, washed, placed in medium or three
concentrations of IFN, and split 1:5 on day 5. Supernatant
medium from day 7 p.i. was assayed in duplicate for RT and
in duplicate for extracellular p24 levels. On day 7 p.i., the
cells were washed twice and lysed in protein extraction
buffer; viral capsid protein p24 levels were determined from
these extracts and normalized to the total protein concentra-
tion in each extract. The extracellular p24 levels and RT
dropped in parallel (about 10-fold at the highest IFN con-
centration) with increasing IFN concentration (Fig. 2A and
B), whereas the intracellular p24 level normalized to protein
concentration dropped by only about 50% at the highest IFN
concentration (Fig. 2C).
Viral protein processing. H9 cells were infected, washed,
and incubated in IFN. On day 5, the medium was sampled
for RT and the cells were split 1:5. The medium was again
sampled on day 8. The cells were counted, and a portion was
lysed in protein extract buffer. Fifty micrograms of total
protein from each culture was electrophoresed on sodium
dodecyl sulfate (SDS)-acrylamide gels, and approximate
levels of viral proteins were determined by Western blot
analysis, with an AIDS patient serum providing primary
antibody (Fig. 3). No changes in viral protein processing
were visible. Similar results were seen in two C3 cell
experiments (data not shown).
Infectivity of virus produced during IFN treatment. Jurkat
and C3 cells were infected and treated in parallel in an
experiment to examine the cell viability and the infectivity of
the progeny virus after IFN treatment. Briefly, 105 Jurkat
cells and 5 x 104 C3 cells per condition in duplicate were
infected, washed, and placed in 48-well plates in 0, 16, 128,
or 512 U of IFN per ml in addition to uninfected cell control
wells. The cells and supematant fluids were harvested from
C3 cells on day 6 p.i. and from the Jurkat cells on day 8 p.i.
The supernatant medium from each duplicate well was
assayed in duplicate for RT and for p24 antigen concentra-
tion. Titers of the virus in C3 supernatant medium were also
VOL. 35, 1991








FIG. 1. Electron micrographs of H9 cells infected with HIV and treated with no IFN (A) or 512 U of IFN per ml (B) for 8 days p.i.
Representative sections show numerous extracellular particles in fields surrounding untreated cells (A) and occasional particles around
IFN-treated cells (B). Bar, 1 ,um.
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FIG. 2. Inhibition of extracellular virus production by IFN. C3
cells were infected, washed, and placed into medium containing 0,
16, 128, or 512 U of IFN per ml and split 1:5 on day 5 p.i. On day 7
p.i., supernatant medium was assayed for extracellular RT (A) and
p24 concentration (B) and protein extracts were made of the washed
cells of each sample. Intracellular p24 concentrations were deter-
mined for the cellular extracts and normalized to the total protein
concentration (C). The standard deviations for RT and p24 measure-
ments were approximately 10 and 15%, respectively.
determined on CEM cells in triplicate by using fivefold
dilutions of supernatant medium. The cell pellets were
counted for total cell number and for percent viable cells, as
assayed by trypan blue exclusion (Table 1). The RT, p24,
and infectious titers from the C3 experiment decreased
approximately equally, when normalized to the infected,
untreated control value (100%b), whereas the absolute num-
ber of viable cells increased about twofold. There was no
indication of a decreased infectivity of virus produced in the
IFN-treated cells. Likewise, in the Jurkat cells, the RT and
p24 concentrations decreased at approximately equal rates,
whereas the viable cell number increased by 50% when the
highest IFN concentration was used. The IFN used in this
experiment had remained at -20°C for more than 1 year with
some loss of activity. Thus the nominal concentration in
units per milliliter is an overestimate; however, the results
concerning relative infectivity are not affected.
Effects of IFN on chronically infected cells. Chronically
infected C3 cells, producing 100,000 cpm of RT on day 0,
were pelleted and placed into new medium containing 0, 32,
or 256 U of IFN per ml. Supernatant medium was sampled
on days 3 and 6 for RT, and protein extracts and RNA











FIG. 3. Detection of viral protein in IFN-treated cells. H9 cells
(Fig. 1A) were incubated in 0, 16, 128, or 512 U of IFN per ml for 5
days and then split 1:5. On day 8 p.i., RNA and protein extracts
were obtained from each sample. Fifty micrograms of protein from
each sample was electrophoresed on SDS-acrylamide gels, and viral
proteins were detected by Western blot analysis with AIDS patient
serum as the primary antibody. Numbers to the left are sizes of viral
proteins in kilodaltons.
RT in the supernatant medium (duplicate determinations)
decreased with increasing IFN concentration to 77% that of
the control culture on day 6 in 256 U/ml (analysis of variance
F ratio, 9.302; P = 0.015) (25). However, the total number of
viable cells decreased to 85% that of the control culture in
the day 6 256-U/ml treatment. Levels of total viral RNA
species remained approximately constant (9.5-, 4.4-, and
1.9-kb species) as seen by Northern (RNA) blot analysis,
and cell-associated viral proteins did not appear to decrease,
as shown by Western blot analysis, nor was processing
altered (data not shown).
In another experiment, chronically infected Jurkat cells
were washed and triplicate wells of 2 x i05 cells were set up
in 1, 32, 128, or 512 U of IFN per ml (day 0). On day 5, the
cells from each well were pelleted; the supernatant medium
was assayed for RT, p24, and infectious titer; and the total
cell pellet was counted for total cell number and viability in
trypan blue. Titers of the virus from the supernatant medium
of two of the wells per condition were determined in tripli-
cate with fivefold dilutions on CEM cells. In this experiment,
the cell viability remained >97% in all wells; the RT, p24
concentration, and titer decreased approximately in propor-
tion to the number of cells, with increasing IFN (Table 2).
DISCUSSION
In these studies, in three human T-lymphocyte cell lines,
at levels of IFN-a that would be achievable in vivo (27), IFN
appeared to decrease virus production, as evidenced by
extracellular RT and p24 antigen levels in the supematant
medium and supported by electron microscopy, whereas
only slight decreases in intracellular viral protein were seen.
Levels of IFN required to inhibit steady-state levels of viral








TABLE 1. Effect of IFN-a on growth and infectivity of HIV in acutely infected ceilsa




Control 94,687 (100) [84,818-104,555] 1.84 (100) [1.53-2.15] 104-03 (100) [3.80-4.26]c 1.20 [0.90-1.50] 0.26 [0.25-0.27]
+IFN (U/ml)d
16 72,344 (76) [70,476-74,212] 1.20 (65) [1.11-1.28] 103.92 (78) [3.80-4.03] 1.00 [0.80-1.20] 0.40 [0.30-0.51]
128 60,040 (63) [54,788-65,292] 0.89 (48) [0.78-1.00] 103.92 (78) [3.804.031 1.12 [1.10-1.14] 0.48 [0.48-0.49]
512 34,728 (37) [31,118-38,338] 0.53 (29) [0.454.61] 103-57 (35) [3.33-3.80] 1.34 [1.30-1.38] 0.57 [0.53-0.61]
Jurkat cells
-Virus 258 1.98 [1.74-2.22]
+Virus
Control 133,689 (100) [122,885-144,493] 1.77 (100) [1.58-1.96] 1.61 [1.45-1.77] 0.98 [0.85-1.12]
+IFN (U/ml)d
16 100,240 (75) [85,427-115,052] 0.93 (53) [0.78-1.07] 1.98 [1.85-2.10] 1.34 [1.15-1.54]
128 97,460 (73) [71,044-123,876] 0.94 (53) [0.79-1.09] 1.91 [1.55-2.27] 1.37 [1.12-1.62]
512 67,494 (50) [56,528-78,459] 0.77 (44) [0.72-0.82] 1.97 [1.52-2.42] 1.45 [1.11-1.79]
a Values in parentheses represent percent positive control. Ranges are shown in brackets. TCID50, 509 tissue culture infective dose.
b Cells were grown in duplicate cultures.
I Log of range of titers.
d IFN concentration in culture.
RNA or protein were much higher than the EC50 of the drug was in sharp contrast to the protective effect of IFN on acute
in C3 cells (9 U/ml). The virus produced in the presence or infection of C3 and Jurkat cells, where both the total cell
absence of IFN appears to be equally infectious, unlike the number and the percent viable cells increased with increas-
effect produced by IFN-a in the cases of Rous sarcoma virus ing concentrations of IFN, while the amount of virus pro-
(28), Moloney murine leukemia virus (26), and mink cell duced decreased.
focus-forming virus (3). Poli et al. (15) reported a similar We considered the possibility that the product of vpu,
decrease in the titer and RT of HIV produced from chroni- which is involved in HIV release, might be one target of IFN
cally HIV-infected Ul and ACH2 cells upon induction with action in this system. In experiments with vpu+ and vpu
TPA (12-0-tetradecanoyl-phorbol-13-acetate) in the pres- mutant clonally derived virus (22), no difference was seen in
ence or absence of IFN-a. Processing of viral gag precursor the effect of IFN upon the replication of these viruses (22a).
protein (p55) does not appear to be inhibited in cellular IFN is known to affect the fluidity of the plasma mem-
protein extracts, nor do the cores of extracellular virus brane (6, 13, 21); it is possible that this change is sufficient to
particles produced in the presence of IFN appear morpho- decrease the formation or budding of new HIV particles
logically different from virions from untreated cells by elec- from the viral proteins present in the cell. Alternatively, the
tron microscopy. The cores of gently isolated cell pellets viral proteins may be present but incorrectly targeted within
showed significantly fewer extracellular particles, and rare the cells so that they are unable to interact, assemble into a
virus budding events were seen after scanning many fields at core, and bud from the cell. We have not ruled out the
the highest IFN concentration used. Taken together, these possibility that earlier steps in the virus life cycle may also
data support a model in which IFN mainly inhibits HIV be affected by IFN-oa.
production at the level of morphogenesis.
The inhibition of HIV production in chronically virus-
producing Jurkat and C3 cells appeared to mainly reflect ACKNOWLEDGMENTS
decreased cell growth in the presence of IFN in both cell This work was supported by Public Health Service grants A123634
types, as the RT and number of total viable cells decreased and A125868 from the National Institute of Allergy and Infectious
to approximately the same extent in these experiments. This Diseases.
TABLE 2. Effect of IFN-a on HIV production and infectivity from chronically infected Jurkat cellsa
Treatmentb RT [p24] Titer % Viable Total cell
(cpm) (,ug/ml) (TCIDdJml) cells no. (106)
-IFN 77,952 (100) [75,460-82,660] 1.12 (100) [1.05-1.20] 103-33 (100) [3.10-3.56]c 98.2 1.27 (100) [1.07-1.53]
+IFN (U/ml)d
16 31,898 (41) [30,014-33,853] 0.65 (58) [0.59-0.73] 103-22 (78) [3.1-3.33] 98.0 1.00 (79) [0.90-1.07]
128 19,799 (25) [18,684-20,649] 0.38 (34) [0.36-0.39] 10328 (89) [3.1-3.45] 97.8 0.69 (54) [0.63-0.81]
512 12,828 (16) [11,447-13,780] 0.26 (24) [0.24-0.28] 103 (59) [2.87-3.33] 98.2 0.47 (37) [0.41-0.53]
a Values in parentheses represent percent positive control. Ranges are shown in brackets. TCID50, 50%o tissue culture infective dose.
b Cells were grown in triplicate cultures.
c Log of range of titers.
d IFN concentration in culture.
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